SBIOALPS Medical Breakthroughs ETF
SBIO Fund Description
SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.
SBIO Factset Analytics Insight
SBIO invests in a concentrated portfolio of biotech companies with drugs in Phase II and Phase III of U.S. Food and Drug Administration (FDA) clinical trials, and limits itself to US-listed firms with market caps between USD 200 million and USD 5 billion. SBIO also screens for sustainability, meaning constituent firms have enough cash on hand to last two years. Given the low historical success rates in clinical trials, the fund is a high-risk, high-reward bet on a small subset of biotech companies. The Underlying Index undergoes semi-annual reconstitution and quarterly rebalance subject to certain caps. The largest stock is capped at 4.5%, and the excess weight is redistributed proportionately over the remainder of the Underlying Index. Prior to July 9, 2019 the fund’s index was Poliwogg Medical Breakthroughs Index, which has the same strategies.
SBIO MSCI ESG Analytics Insight
ALPS Medical Breakthroughs ETF has an MSCI ESG Fund Rating of BB based on a score of 4.41 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.
The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. ALPS Medical Breakthroughs ETF ranks in the 15th percentile within its peer group and in the 27th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.
SBIO MSCI FaCS and Factor Box
MSCI FaCS is a standard method for evaluating and reporting the Factor characteristics of equity portfolios including ETFs. The Factor Box includes 6 Factors that MSCI has identified that historically provided a return premium. On the vertical axis, the Factor Groups, are displayed and the horizontal axis displays the Factor exposure, overweight, underweight or neutral.
SBIO Portfolio Data
SBIO Index Data
SBIO Portfolio Management
SBIO Tax Exposures
SBIO Fund Structure
SBIO Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of SBIO. SBIO is rated a 5 out of 5.
SBIO Sector/Industry Breakdown
SBIO Top 10 Holdings[View All]
SBIO Economic Development
SBIO Performance Statistics
SBIO MSCI ESG Ratings
SBIO Benchmark Comparison Summary
SBIO Benchmark Comparison Market Cap Size